A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines

Vaccine

Volumn 35, Issue 24, 2017, Pages 3162-3170

  Chada, Kinnera E ^a   Forshee, Richard ^a   Golding, Hana ^a   Anderson, Steven ^a   Yang, Hong ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Adjuvanted influenza vaccines; Avian influenza; Cross clade immunogenicity; Cross reactivity; Pandemic preparedness; Stockpiled influenza vaccines

Indexed keywords

CROSS REACTING ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; WATER OIL CREAM; OIL; VIRUS ANTIBODY; WATER;

CLADISTICS; CLINICAL OUTCOME; CROSS REACTION; HUMAN; INFLUENZA A VIRUS (H5N1); META ANALYSIS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SEROLOGY; SYSTEMATIC REVIEW; VACCINE IMMUNOGENICITY; VIRUS STRAIN; ADOLESCENT; ADULT; EMULSION; FEMALE; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA; MALE; MIDDLE AGED; PANDEMIC; TRANSMISSION; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CROSS REACTIONS; EMULSIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOGENICITY, VACCINE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OILS; PANDEMICS; WATER; YOUNG ADULT;

EID: 85018783267     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.04.029     Document Type: Review

References (61)

1. Del, G.G., Fragapane, E., Della, C.G., Rappuoli, R., Aflunov(R): a vaccine tailored for pre-pandemic and pandemic approaches against influenza. Expert Opin Biol Ther 13 (2013), 121–135.
2. Khurana, S., Verma, S., Verma, N., Crevar, C.J., Carter, D.M., Manischewitz, J., et al. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets. J Virol 85 (2011), 1246–1256.
3. Herfst, S., Schrauwen, E.J., Linster, M., Chutinimitkul, S., de, W.E., Munster, V.J., et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336 (2012), 1534–1541.
4. Imai, M., Herfst, S., Sorrell, E.M., Schrauwen, E.J., Linster, M., De Graaf, M., et al. Transmission of influenza A/H5N1 viruses in mammals. Virus Res 178 (2013), 15–20.
5. Rockman, S., Brown, L., Pre-pandemic and pandemic influenza vaccines. Hum Vaccin 6 (2010), 792–801.
6. Aflunov. Prepandemic influenza H5N1 vaccine (surface antigen, inactivated, adjuvanted). Committee for Medicinal Products for Human Use (CHMP). 2011.
7. H5N1 vaccine approved by the U.S. FDA as pandemic influenza preparedness measure. GlaxoSmithKline press release. 2013.
8. Bihari, I., Panczel, G., Kovacs, J., Beygo, J., Fragapane, E., Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects. Clin Vaccine Immunol 19 (2012), 1943–1948.
9. Hoelscher, M., Gangappa, S., Zhong, W., Jayashankar, L., Sambhara, S., Vaccines against epidemic and pandemic influenza. Expert Opin Drug Deliv 5 (2008), 1139–1157.
10. Leroux-Roels, G., Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 9 (2009), 1057–1071.
11. Jennings, L.C., Monto, A.S., Chan, P.K., Szucs, T.D., Nicholson, K.G., Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 8 (2008), 650–658.
12. Sambhara, S., Poland, G.A., H5N1 Avian influenza: preventive and therapeutic strategies against a pandemic. Annu Rev Med 61 (2010), 187–198.
13. Leroux-Roels, I., Borkowski, A., Vanwolleghem, T., Drame, M., Clement, F., Hons, E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 (2007), 580–589.
14. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (revision). Committee for guidance for human medicinal products (CHMP). EMEA/CPMP/VEG/4717/2003- Rev. 1. 2008.
15. Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines. Center for Biologics Evaluation and Research (CBER). 2009.
16. Pumarix. Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted). Committee for Medicinal Products for Human Use (CHMP). 2011.
17. Khurana, S., Chearwae, W., Castellino, F., Manischewitz, J., King, L.R., Honorkiewicz, A., et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med, 2, 2010 15ra5.
18. Khurana, S., Verma, N., Yewdell, J.W., Hilbert, A.K., Castellino, F., Lattanzi, M., et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med, 3, 2011, 85ra48.
19. Palache, B., Krause, R., Progress with human H5N1 vaccines: a perspective from industry. Expert Rev Vaccines 8 (2009), 391–400.
20. Guideline on influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context. Committee for Guidance for Human Medicinal Products (CHMP).EMEA/CHMP/VWP/263499/2006. 2007.
21. Manzoli, L., Salanti, G., De, V.C., Boccia, A., Ioannidis, J.P., Villari, P., Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis. Lancet Infect Dis 9 (2009), 482–492.
22. Manzoli, L., Ioannidis, J.P., Flacco, M.E., De, V.C., Villari, P., Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly: a critical review and re-analysis of 15 meta-analyses. Hum Vaccin Immunother 8 (2012), 851–862.
23. Prieto-Lara, E., Llanos-Mendez, A., Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature. Vaccine 28 (2010), 4328–4334.
24. Risi, G., Frenette, L., Langley, J.M., Li, P., Riff, D., Sheldon, E., et al. Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months. Vaccine 31 (2013), 436–437.
25. Carter, N.J., Plosker, G.L., Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs 22 (2008), 279–292.
26. Gasparini, R., Amicizia, D., Lai, P.L., Panatto, D., Aflunov((R)): a prepandemic influenza vaccine. Expert Rev Vaccines 11 (2012), 145–157.
27. Bidwelld S, Jensen MF. Chapter 3: Using a Search Protocol to Identify Sources of Information: the COSI Model. In: I A, LA T, editors. Etext on Health Technology Assessment (HTA) information resources. Bethesda, MD: National Information Center on Health Services Research and Health Care Technology (NICHSR) of the U.S. National Library of Medicine; 2008.
28. Jadad, A.R., Moore, R.A., Carroll, D., Jenkinson, C., Reynolds, D.J., Gavaghan, D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996), 1–12.
29. Banzhoff, A., Gasparini, R., Laghi-Pasini, F., Staniscia, T., Durando, P., Montomoli, E., et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE, 4, 2009, e4384.
30. Chu, D.W., Hwang, S.J., Lim, F.S., Oh, H.M., Thongcharoen, P., Yang, P.C., et al. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 27 (2009), 7428–7435.
31. Czajka, H., Unal, S., Ulusoy, S., Usluer, G., Strus, A., Sennaroglu, E., et al. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects. J Prev Med Hyg 53 (2012), 136–142.
32. Galli, G., Hancock, K., Hoschler, K., DeVos, J., Praus, M., Bardelli, M., et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci U S A 106 (2009), 7962–7967.
33. Gillard, P., Caplanusi, A., Knuf, M., Roman, F., Walravens, K., Moris, P., et al. An assessment of prime-boost vaccination schedules with AS03A-adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Influenza Other Respir Viruses 7 (2013), 55–65.
34. Langley, J.M., Frenette, L., Ferguson, L., Riff, D., Sheldon, E., Risi, G., et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 201 (2010), 1644–1653.
35. Langley, J.M., Risi, G., Caldwell, M., Gilderman, L., Berwald, B., Fogarty, C., et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis 203 (2011), 1729–1738.
36. Schwarz, T.F., Horacek, T., Knuf, M., Damman, H.G., Roman, F., Drame, M., et al. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults. Vaccine 27 (2009), 6284–6290.
37. Langan, D., Higgins, J.P., Gregory, W., Sutton, A.J., Graphical augmentations to the funnel plot assess the impact of additional evidence on a meta-analysis. J Clin Epidemiol 65 (2012), 511–519.
38. Crowther, M.J., Langan, D., Sutton, A.J., Graphical augmentations to the funnel plot to assess the impact of a new study on an existing meta-analysis. Stata J. 12 (2012), 605–622.
39. Leroux-Roels, I., Bernhard, R., Gerard, P., Drame, M., Hanon, E., Leroux-Roels, G., Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE, 3, 2008, e1665.
40. Beran, J., Abdel-Messih, I.A., Raupachova, J., Hobzova, L., Fragapane, E., A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. Clin Ther 32 (2010), 2186–2197.
41. Vesikari, T., Forsten, A., Herbinger, K.H., Cioppa, G.D., Beygo, J., Borkowski, A., et al. Safety and immunogenicity of an MF59((R))-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine 30 (2012), 1388–1396.
42. Lasko, B., Reich, D., Madan, A., Roman, F., Li, P., Vaughn, D., Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03(A)-adjuvanted vaccination in adults. J Infect Dis 204 (2011), 574–581.
43. Nagai, H., Ikematsu, H., Tenjinbaru, K., Maeda, A., Drame, M., Roman, F.P., A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults. BMC Infect Dis, 10, 2010, 338.
44. Yang, P.C., Yu, C.J., Chang, S.C., Hsieh, S.M., Drame, M., Walravens, K., et al. Safety and immunogenicity of a split-virion AS03A-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine in Taiwanese adults. J Formos Med Assoc 111 (2012), 333–339.
45. Izurieta, P., Kim, W.J., Wie, S.H., Lee, J., Lee, J.S., Drame, M., et al. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study. Vaccine 33 (2015), 2800–2807.
46. Viechtbauer, W., Cheung, M.W., Outlier and influence diagnostics for meta-analysis. Res Synth Methods 1 (2010), 112–125.
47. Fragapane, E., Gasparini, R., Schioppa, F., Laghi-Pasini, F., Montomoli, E., Banzhoff, A., A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly. Clin Vaccine Immunol 17 (2010), 1817–1819.
48. Alberini, I., Del, T.E., Fasolo, A., Temperton, N.J., Galli, G., Gentile, C., et al. Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 27 (2009), 5998–6003.
49. Buricchi, F., Bardelli, M., Malzone, C., Capecchi, B., Nicolay, U., Fragapane, E., et al. Impact of preexisting memory to seasonal A/H1N1 influenza virus on the immune response following vaccination against avian A/H5N1 virus. Eur J Immunol 43 (2013), 641–648.
50. Stephenson, I., Bugarini, R., Nicholson, K.G., Podda, A., Wood, J.M., Zambon, M.C., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191 (2005), 1210–1215.
51. Belshe, R.B., Frey, S.E., Graham, I., Mulligan, M.J., Edupuganti, S., Jackson, L.A., et al. Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant. J Infect Dis 203 (2011), 666–673.
52. Xie, H., Jing, X., Li, X., Lin, Z., Plant, E., Zoueva, O., et al. Immunogenicity and cross-reactivity of 2009–2010 inactivated seasonal influenza vaccine in US adults and elderly. PLoS ONE, 6, 2011, e16650.
53. Kitphati, R., Pooruk, P., Lerdsamran, H., Poosuwan, S., Louisirirotchanakul, S., Auewarakul, P., et al. Kinetics and longevity of antibody response to influenza A H5N1 virus infection in humans. Clin Vaccine Immunol 16 (2009), 978–981.
54. Rowe, T., Abernathy, R.A., Hu-Primmer, J., Thompson, W.W., Lu, X., Lim, W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37 (1999), 937–943.
55. Diez-Domingo, J., Garces-Sanchez, M., Baldo, J.M., Planelles, M.V., Ubeda, I., JuBert, A., et al. Immunogenicity and Safety of H5N1 A/Vietnam/1194/2004 (Clade 1) AS03-adjuvanted prepandemic candidate influenza vaccines in children aged 3 to 9 years: a phase ii, randomized, open, controlled study. Pediatr Infect Dis J 29 (2010), e35–e46.
56. Vesikari, T., Forsten, A., Borkowski, A., Gaitatzis, N., Banzhoff, A., Clemens, R., Homologous and heterologous antibody responses to a one-year booster dose of an MF59((R)) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects. Hum Vaccin Immunother 8 (2012), 921–928.
57. Ferguson, N.M., Cummings, D.A., Fraser, C., Cajka, J.C., Cooley, P.C., Burke, D.S., Strategies for mitigating an influenza pandemic. Nature 442 (2006), 448–452.
58. Leroux-Roels, I., Roman, F., Forgus, S., Maes, C., De, B.F., Drame, M., et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 28 (2010), 849–857.
59. Khurana, S., Coyle, E.M., Dimitrova, M., Castellino, F., Nicholson, K., Del, G.G., et al. Heterologous prime-boost vaccination with MF59-adjuvanted H5 vaccines promotes antibody affinity maturation towards the hemagglutinin HA1 domain and broad H5N1 cross-clade neutralization. PLoS ONE, 9, 2014, e95496.
60. Madan, A., Ferguson, M., Rheault, P., Seiden, D., Toma, A., Friel, D., et al. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial. Vaccine 35 (2017), 1865–1872.
61. Mallett, C.P., Beaulieu, E., Joly, M.H., Baras, B., Lu, X.H., Liu, F., et al. AS03-adjuvanted H7N1 detergent-split virion vaccine is highly immunogenic in unprimed mice and induces cross-reactive antibodies to emerged H7N9 and additional H7 subtypes. Vaccine 33 (2015), 3784–3787.